STX-001 is under clinical development by Strand Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STX-001 overview

STX-001 is under development for the treatment of solid tumor including Melanoma and triple-negative breast cancer (TNBC). The therapeutic candidates comprised of engineered mRNA, administered with certain immunotherapies. it is a locally administered LNP-formulated synthetic self-replicating mRNA that encodes the therapeutic payload IL-12. It is administered through intertumoral route.

Strand Therapeutics overview

Strand Therapeutics is a biopharmaceutical company specialized in developing mRNA drugs and gene therapies for curative treatments in oncology and solid tumors. Strand Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of STX-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.